Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis

Area of Science:

• Oncology
• Molecular Biology
• Clinical Trials

Background:

• Metastatic colorectal cancer (mCRC) treatment often involves anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs).
• The predictive role of Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in anti-EGFR therapy response remains a key research area.
• Understanding KRAS status is crucial for optimizing mCRC treatment strategies.

Purpose of the Study:

• To evaluate the correlation between KRAS mutation status and the efficacy of anti-EGFR MoAbs in mCRC patients.
• To determine if KRAS status can predict clinical benefit from anti-EGFR therapies.
• To analyze the impact of KRAS status on progression-free survival (PFS) and overall survival (OS).

Main Methods:

• A meta-analysis of ten randomized controlled trials (RCTs) involving mCRC patients treated with anti-EGFR MoAbs.
• Investigation of the association between KRAS mutation status and clinical outcomes (PFS and OS).
• Statistical analysis to assess the strength of the relationship between KRAS mutation and treatment response.

Main Results:

• Survival benefit from first-line anti-EGFR MoAbs was observed exclusively in patients with wild-type KRAS.
• Oxaliplatin-based chemotherapy did not show significant benefit for wild-type KRAS mCRC patients.
• Clinical benefit was limited to fluorouracil-based therapy combined with anti-EGFR MoAbs, irrespective of treatment line.
• Anti-EGFR MoAbs provided clinical benefit only to wild-type KRAS patients, even in second- or further-line treatments.

Conclusions:

• KRAS status serves as a significant predictive biomarker for anti-EGFR MoAb therapy in mCRC.
• Identifying KRAS wild-type status is essential for patient selection in anti-EGFR targeted therapy.
• This finding supports personalized treatment approaches in mCRC based on KRAS mutational profile.